Jiangsu Kanion Pharmaceutical is a large cross-regional pharmaceutical group that features integration of scientific research, industrial production and sale for herb medicines. It is among the first 50 of the top 100 Chinese pharmaceutical enterprises and list in the top 5 of Traditional Chinese Medicine Industries. In 2014, the group company has achieved sales revenues at 5.2 billion with profit tax 938 million and the corporation achieved sales revenues at 2.2 billion with profit tax 674 million.

With more than 200 research staffs, half of which are with master and doctor degree, Kanion has built an open research center for new Chinese medicine of the national-level. It successively developed about 40 new state level drugs, accessed to domestic and foreign invention patent over 280 pieces, and obtained over 190 authorization of invention patent. Kanion has built 10 co-constructed labs through industry-university-institution cooperation. Besides, it has established the R&D Company for new medicine in US. Kanion own the most state level new medicines, the most independent intellectual property patents and the most contribution to promote research of the TCM internationalization,

Kanion has built up three factories successively, two of those located in Lianyungang of Jiangsu Province and one in Nanjing, the capital of Jiangsu Province. With annual processing capacity of 10, 000 ton raw medicinal materials, Kanion has the biggest intelligence production line of traditional Chinese medicinal materials extraction. All the 13 production lines have successively passed the latest GMP authentication. The refining extraction line with the most leading and advancing automatic, an intelligence facility which is under construction since November 2012 would come into use in 2014.

With a marketing team of 2500 well-educated and professional crews, Kanion has built a professional and academic marketing net covering 28 provinces by 29 sales branches and over 100 offices, establishing a stable long term relationship with over 800 Pharmaceutical Business Companies with production covering over 7000 medical treatment units above the county level.

Besides, Kanion specialize in providing OEM service on food supplements for oversea market for many years. Products have been mainly sold to North America, Australia, South Africa, EU and so on. Sales revenues reached over RMB50 million in 2013.

Focusing on modern herb medicines, herb health care products and marine drugs, Kanion will continue to adhere to the independent innovation, comprehensively enhance core competitiveness, and promote the modernization and internationalization of TCM, to be a health industry group with annual sales over ten billion yuan(USD1, 500, 000, 000), profit and tax of 2 billion yuan(USD300, 000, 000), to be the leading company on TCM treatments on gynaecology, antivirus, Orthopedics and cardiovascular and cerebrovascular.